Leukemia, Lymphocytic, Chronic, B-Cell Concept

Vocabulary Service

MeSH

Overview

subject area of

A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed ch Academic Article
Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia Academic Article
Abnormalities in T-cell associated rearrangement of T-cell receptor gamma chain genes in B-cell chronic lymphocytic leukemia Academic Article
Adjunctive therapy (whole body hyperthermia versus lonidamine) to total body irradiation for the treatment of favorable b-cell neoplasms: a report of two pilot clinical trials and laboratory investigations Academic Article
An atypical case of bilateral posterior scleritis in a patient with chronic lymphocytic leukemia Academic Article
Angiomatosis of skin with local intravascular immunoglobulin deposits, associated with monoclonal gammopathy. A potential cutaneous marker for B-chronic lymphocytic leukemia. Academic Article
Canadian evidence-based guideline for the first-line treatment of chronic lymphocytic leukemia Academic Article
Central Nervous System Involvement with Chronic Lymphocytic Leukemia Academic Article
DNA repair enzyme expression in chronic lymphocytic leukemia vis-à-vis nitrogen mustard drug resistance Academic Article
Engraftment of human chronic lymphocytic leukemia cells in SCID mice: in vivo and in vitro studies. Academic Article
Generation ofin vitroB-CLL specific HLA class I restricted CTL responses using autologous dendritic cells pulsed with necrotictumor lysate Academic Article
High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells Academic Article
INDEPENDENT CLONAL ORIGIN OF COEXISTING CHRONIC LYMPHOCYTIC LEUKAEMIA AND MULTIPLE MYELOMA Academic Article
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study Academic Article
Increased DNA Synthesis and Repair-Enzyme Expression in Lymphocytes From Patients With Chronic Lymphocytic Leukemia Resistant to Nitrogen Mustards Academic Article
Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells Academic Article
Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial Academic Article
Leukemia Cutis Presenting with Fingertip Hypertrophy Academic Article
Monoclonal gammopathy and glomerulopathy associated with chronic lymphocytic leukemia Academic Article
Nitrogen mustard drug resistant B-cell chronic lymphocytic leukemia as an in vivo model for crosslinking agent resistance Academic Article
Poly(ADP-ribose) polymerase can bind melphalan damaged DNA. Academic Article
Potentiation of chlorambucil toxicity in B-CLL lymphocytes using the DNA synthesis inhibitors aphidicolin and 1-β-d-arabinofuranosylcytosine Academic Article
Recent advances in immunotherapy of B-CLL using ex vivo modified dendritic cells Academic Article
Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline Academic Article
Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma Academic Article
Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial* Academic Article
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial Academic Article
Telomerase activity in normal leukocytes and in hematologic malignancies Academic Article
The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group Academic Article
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma Academic Article